DNAvaccine.com Presents: Vector Design for Vaccine and Gene Therapy Applications with Dr. Jim Williams from Nature Technology
Join us for a Webinar on April 24
Abstract:
Extensive research to improve plasmid delivery has resulted in advanced methods such as electroporation that dramatically improve gene transfer compared with naked DNA delivery. Plasmid-directed gene expression is now near the efficacy barrier that to date has prevented DNA medicine commercialization for human applications. However, most DNA vaccines and non-viral gene therapeutics currently in development utilize suboptimal vector backbones. In this webinar I will discuss DNA vaccine vector and synthetic gene insert design strategies that may be applied to create regulatory agency compliant non viral plasmid vectors with improved transgene expression and immunogenicity.
-
Brief Biography:
Dr. Williams is the Chief Scientific Officer and Vice President, Research and Development, at Nature Technology Corporation (NTC). Dr. Williams has 17 years biotech industry experience directing microbial fermentation, cell line, & vector design programs for protein & DNA-based vaccine or therapeutic product applications. He oversaw development of NTC’s minimal antibiotic-free plasmid vector/manufacturing platform for DNA vaccination and gene therapy applications.
Title
DNAvaccine.com Presents: Vector design for vaccine and gene therapy applications
Date
Tuesday, April 24, 2012
Time
1:00 PM – 2:00 PM EDT
After registering you will receive a confirmation email containing information about joining the Webinar.
System Requirements
PC-based attendees
Required: Windows® 7, Vista, XP or 2003 Server
Macintosh®-based attendees
Required: Mac OS® X 10.5 or newer
Space is limited.
Reserve your Webinar seat now at:
